Thunderstruck By OpenEvidence’s $12B Valuation? Don’t Be. 

OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 430,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate. The post Thunderstruck By…

Read More

With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen

FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared…

Read More